Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.

CEO

ISIN

SE0022239950

Listings

0 Comments

Share your thoughts

FAQ

What is Mendus AB stock price today?▼

The current price of 1YG0.MU is €0.47 EUR — it has decreased by -1.66% in the past 24 hours. Watch Mendus AB stock price performance more closely on the chart.

What is Mendus AB stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Mendus AB stocks are traded under the ticker 1YG0.MU.

Is Mendus AB stock price growing?▼

1YG0.MU stock has fallen by -2.27% compared to the previous week, the month change is a +6.27% rise, over the last year Mendus AB has showed a -0.32% decrease.

When is the next Mendus AB earnings date?▼

Mendus AB is going to release the next earnings report on August 20, 2026.

In which sector is Mendus AB located?▼

Mendus AB operates in the Other sector.

When did Mendus AB complete a stock split?▼

Mendus AB has not had any recent stock splits.